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Upon antigen stimulation, naive T cells undergo 
extensive clonal expansion and differentiation 
for immune defense and regulation. A defining 
feature of T cell activation is the marked in-
crease of the bioenergetic demands over the rest-
ing state. Activated T cells are highly anabolic 
and demonstrate a striking increase in glycolysis, 
as well as an increase in glucose and amino acid 
uptake (Fox et al., 2005; Jones and Thompson, 
2007; Pearce, 2010). The reliance on glycolysis 
(even in the presence of high levels of oxygen) 
to generate ATP, which is far less efficient than 
oxidative phosphorylation, is an unusual meta-
bolic aspect of proliferating T cells and cancer 
cells, the latter of which is known as the Warburg 
effect (Warburg, 1956). Fox et al. (2005) and 
Jones  and  Thompson  (2007)  have  proposed 
that up-regulation of T cell metabolism is not 
merely a consequence of increased activation but 
rather a necessary step to facilitate activation. In 
support of this notion, proper regulation of 
glucose and sterol metabolism is required for 
the development of adaptive immune responses 
(Bensinger and Tontonoz, 2008; Bensinger et al., 
2008; Cham et al., 2008). Conversely, anergic 
T cells fail to up-regulate the machinery neces-
sary to support increased metabolism (Delgoffe 
et al., 2009; Zheng et al., 2009), whereas mem-
ory cell formation requires a lower metabolic 
activity (Araki et al., 2009; Pearce et al., 2009). 
Although a role for the metabolic pathways in 
T cell activation and responses is beginning to 
be appreciated, little information exists on their 
involvement in the differentiation of T cell 
functional subsets.
Discrete effector populations can develop 
from naive T cells to mediate specialized im-
mune functions and are characterized by unique 
patterns of cytokine secretion. IFN-, IL-4, and 
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Upon antigen stimulation, the bioenergetic demands of T cells increase dramatically over the 
resting state. Although a role for the metabolic switch to glycolysis has been suggested to 
support increased anabolic activities and facilitate T cell growth and proliferation, whether 
cellular metabolism controls T cell lineage choices remains poorly understood. We report 
that the glycolytic pathway is actively regulated during the differentiation of inflammatory 
TH17 and Foxp3-expressing regulatory T cells (Treg cells) and controls cell fate determination. 
TH17 but not Treg cell–inducing conditions resulted in strong up-regulation of the glycolytic 
activity and induction of glycolytic enzymes. Blocking glycolysis inhibited TH17 development 
while promoting Treg cell generation. Moreover, the transcription factor hypoxia-inducible 
factor 1 (HIF1) was selectively expressed in TH17 cells and its induction required signal-
ing through mTOR, a central regulator of cellular metabolism. HIF1–dependent transcrip-
tional program was important for mediating glycolytic activity, thereby contributing to the 
lineage choices between TH17 and Treg cells. Lack of HIF1 resulted in diminished TH17 
development but enhanced Treg cell differentiation and protected mice from autoimmune 
neuroinflammation. Our studies demonstrate that HIF1–dependent glycolytic pathway 
orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.
© 2011 Shi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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with a very recent study (Michalek et al., 2011), TH1, TH2, 
and TH17 cells contained much higher glycolytic activity than 
Treg cells (Fig. 1 A), indicating strong up-regulation of glu-
cose metabolism in effector T cells.
We next tested whether the differential activity of glycoly-
sis between effector and regulatory T cells is transcriptionally 
regulated. A key transcription factor orchestrating the expres-
sion of glycolytic enzymes is HIF1, a heterodimer comprised 
of  (HIF1) and  (HIF1) subunits (Nizet and Johnson, 
2009). Although HIF1 has been implicated in T cell responses 
(Neumann et al., 2005; Lukashev et al., 2006), its function 
and regulation in T cell differentiation remain undefined. To 
determine the intrinsic function of HIF1 in T cells, we first 
examined expression of HIF1, the regulated component of 
the complex. Although HIF1 is known to be induced by 
hypoxic conditions through a posttranslational-dependent 
mechanism, HIF1 can be up-regulated by NF-B signaling 
in activated innate immune cells under normoxia (Rius et al., 
2008; Nizet and Johnson, 2009). HIF1 was strongly induced 
at the protein level in T cells undergoing TH17 differentia-
tion, whereas the lowest levels were found in Treg cells. More-
over, mRNA levels of HIF1 were also highly induced in 
T cells undergoing TH17 differentiation (Fig. 1 B). These results 
identify a selective up-regulation of HIF1 under TH17-
  polarizing conditions.
To investigate the role of HIF1 in T cell differentiation, we 
crossed mice carrying a conditional HIF1 allele (HIF1flox/flox; 
Ryan et al., 2000) with CD4-Cre transgenic mice to delete 
the floxed HIF1 allele specifically in T cells (called HIF1–/– 
mice thereafter). Real-time PCR analyses indicated efficient 
deletion of the HIF1 gene in T cells (Fig. 1 C). WT and 
HIF1/ mice contained similar numbers and distribution of 
thymocytes and peripheral CD4 and CD8 T cells (Fig. S1 A). 
Also, development and homeostasis of natural Treg cells ap-
peared to be largely undisturbed (Fig. S1 B). Cell prolifera-
tion and apoptosis in response to TCR stimulation were also 
comparable between WT and HIF1/ T cells (Fig. S1, C 
and D). To examine whether HIF1 controls glycolytic activity 
in TH17 cells, we purified naive T cells from WT and HIF1/ 
mice and differentiated them under TH17-polarizing condi-
tions. Deficiency in HIF1 resulted in greatly reduced gly-
colytic activity (Fig. 1 D), indicating an important role for 
HIF1 to promote glycolysis in TH17 differentiation.
Glucose utilization depends on a chain of reactions cata-
lyzed by multiple enzymes, eventually leading to the genera-
tion of lactate and net production of two ATP molecules as 
the energy source. In addition, glucose transport 1 (Glut1) and 
monocarboxylic acid transporter member 4 (MCT4) serve as 
plasma membrane transporters for glucose uptake and lactate 
export, respectively (Fig. 1 E). Real-time PCR analyses of 
WT cells undergoing TH17 differentiation revealed marked 
up-regulation of genes encoding various molecules involved 
in glycolysis (Fig. 1 F). These include the transporters Glut1 
and MCT4 and glycolytic enzymes HK2 (hexokinase 2), GPI 
(glucose-6-phosphate isomerase), TPI (triosephosphate isom-
erase), Eno1 (enolase 1), PKM (pyruvate kinase muscle), and 
IL-17 are the signature cytokines for TH1, TH2, and TH17 
cells, respectively. In contrast, induced Foxp3+ regulatory T cells 
(Treg cells) act in synergy with natural Treg cells to promote 
immune tolerance and inhibit autoimmunity (Littman and 
Rudensky, 2010; Zhu et al., 2010). Induction of Treg cells in 
the peripheral immune compartment is closely related to the 
generation of TH17 cells, as the differentiation of both lin-
eages is dependent on the pleiotropic cytokine TGF- (Bettelli 
et al., 2006). Also, ROR-t and Foxp3, the respective lineage-
specific transcription factors for TH17 and Treg cells, are co-
expressed in naive CD4 T cells exposed to TGF-, but Foxp3 
is dominant and antagonizes ROR-t function unless IL-6 is 
present (Zhou et al., 2008). Thus, an inflammatory environ-
ment controls the balance between Treg and TH17 cell differ-
entiation. The cytokines and environmental signals trigger a 
signaling cascade culminating in the transcriptional induction 
of lineage-specific cytokines and effector molecules. In par-
ticular, mTOR, a central regulator of cellular metabolism and 
protein translation, integrates various extracellular and intra-
cellular signals to promote effector but not regulatory T cell 
differentiation (Delgoffe et al., 2009; Powell and Delgoffe, 
2010). However, it remains unknown whether the basic meta-
bolic machinery is actively regulated and contributes to T cell 
differentiation.
In this paper, we show that TH17 and Treg cells have marked 
differences in their glycolytic activity and expression of gly-
colytic  enzymes.  Combining  pharmacological  and  genetic 
approaches, we found that glycolysis serves as a key metabolic 
checkpoint to direct the cell fate determination between TH17 
and Treg cells. Specifically, the glucose analogue 2-deoxyglucose 
(2-DG), a prototypical inhibitor of the glycolytic pathway, 
dampened the development of T cells into TH17 cells while 
promoting Treg cell generation. In addition, deficiency in the 
transcription factor hypoxia-inducible factor 1 (HIF1) in 
T cells diminished expression of the glycolytic molecules and 
altered the dichotomy between these two T cell lineages. 
Moreover, the HIF1–dependent glycolytic pathway is down-
stream of mTOR signaling, thereby contributing to mTOR-
mediated T cell differentiation. Our studies demonstrate that 
HIF1–induced metabolic reprogramming orchestrates lin-
eage differentiation of T cells.
RESULTS AND DISCUSSION
TH17-polarizing conditions induce HIF1–dependent 
glycolytic activity
Although it has been well appreciated that T cell activation is 
accompanied by a metabolic switch to glycolysis (Fox et al., 
2005; Jones and Thompson, 2007; Pearce, 2010), how glyco-
lytic activity is regulated during T cell differentiation is poorly 
understood.  We  therefore  measured  glycolytic  activity  in 
various CD4 T cell lineages. To this end, we activated naive 
T cells under polarizing conditions in vitro and obtained TH1, 
TH2, TH17, and Treg cells with selective expression of IFN-, 
IL-4, IL-17, and Foxp3, respectively (Fig. 1 A). The glyco-
lytic activity of differentiated cells was measured by the gen-
eration of 3H-labeled H2O from [3-3H]-glucose. In agreement JEM Vol. 208, No. 7  1369
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parable level of IL-2, relative to WT cells (Fig. 2 B). Real-
time PCR analyses revealed decreased expression of the TH17 
family cytokines IL-17, IL-17F, IL-21, and IL-22 (Fig. 2 C). 
Thus, HIF1 deficiency results in impairment in the TH17 
differentiation program. In contrast, in vitro differentiation of 
TH1  and  TH2  effector  cells  was  largely  independent  of 
HIF1 (Fig. S2 C).
T cell differentiation is programmed by coordinated in-
duction of transcription factors and cytokine receptors to 
facilitate the establishment of specific lineages (Littman and 
Rudensky, 2010; Zhu et al., 2010). To identify mechanisms 
of defective TH17 differentiation in HIF1/ cells, we ex-
amined the expression of transcription factors and cytokine re-
ceptors involved in TH17 differentiation. Expression of ROR-, 
ROR-t, AHR, IRF4, IL-6R, and IL-21R and the phos-
phorylation of Stat3 were comparable between differentiating 
WT and HIF1/ cells (unpublished data). In contrast, ex-
pression of IL-23R was significantly down-regulated (Fig. 2 D), 
whereas Foxp3 was up-regulated (Fig. 2 E), in HIF1/ 
cells under TH17-polarizing conditions. IL-23R is essential for 
terminal differentiation of TH17 cells (McGeachy et al., 2009), 
whereas Foxp3, the Treg cell master regulator, has been shown 
to antagonize ROR-t function and TH17 differentiation 
LDH- (lactate dehydrogenase), thus encompassing the entire 
spectrum of the glycolytic pathway. In contrast, expression 
levels of these molecules were much lower in HIF1/  
cells cultured under similar conditions (Fig. 1 F). Therefore, 
HIF1 establishes the glycolytic gene expression program in 
TH17 cells.
HIF1 is required for TH17 differentiation
Having demonstrated a role for HIF1 in mediating glycoly-
sis in TH17 cells, we next explored the functional require-
ment of HIF1 in effector T cell differentiation. Naive T cells 
from WT and HIF1/ mice were differentiated under TH17 
conditions, and expression of IL-17 was examined by intra-
cellular staining. As compared with WT cells, HIF1/ cells 
exhibited a reduction of IL-17+ cells (Fig. 2 A). CFSE dilution 
assays revealed a similar degree of proliferation between WT 
and HIF1/ cells, indicating that the defective IL-17 pro-
duction was largely independent of cell expansion (Fig. S2 A). 
In addition, impaired IL-17 production was observed in 
HIF1/ cells, regardless of the inclusion of IL-23 or block-
ing antibodies to potentiate TH17 differentiation (Fig. S2 B). 
Furthermore, upon TCR restimulation, effector TH17 cells 
lacking HIF1 secreted a lower amount of IL-17, but a com-
Figure 1.  TH17-inducing conditions elicit 
HIF1–dependent up-regulation of gly-
colytic activity. (A) Sorted naive T cells 
(CD4+CD62LhiCD44loCD25) from WT mice 
were differentiated under TH1, TH2, TH17, or 
Treg cell–inducing conditions for 5 d, followed 
by intracellular staining of IFN- and IL-4 
(TH1/TH2) or IL-17 and Foxp3 (TH17/Treg; left). 
The glycolytic activity of these cells was mea-
sured by the generation of 3H-labeled H2O 
from [3-3H]-glucose (right). (B) HIF1 expres-
sion was examined by Western blot (top) and 
real-time PCR analyses (bottom) in T cells 
activated under various conditions for 2.5 d. 
HIF1 mRNA levels in naive cells were set to 1. 
For Western blotting, samples were from dif-
ferent parts of the same gel with the same 
exposure. Black lines indicate that intervening 
lanes were spliced out. (C) HIF1 mRNA  
expression was examined in WT and HIF1/ 
naive T cells and in cells differentiated under 
TH17 conditions for 2.5 d. (D) Naive T cells 
from WT and HIF1/ mice were differenti-
ated under TH17 conditions, followed by mea-
surement of glycolytic activity. (E) Diagram of 
the glycolytic pathway, with the molecules 
measured highlighted in blue. (F) RNA was 
isolated from naive T cells from WT and 
HIF1/ mice, or those differentiated under 
TH17 conditions for 2.5 d, and used for real-
time PCR analyses of glycolytic molecules. 
Expression levels in WT naive T cells were set 
to 1. Data in Fig. 1 are representative of two 
to three independent experiments. Data rep-
resent the mean ± SD.1370 A metabolic checkpoint in T cell differentiation | Shi et al.
enzymes described in Fig. 1 F, all of which were markedly 
down-regulated in HIF1/ cells. HIF1/ cells also showed 
altered expression of transcription factors, signaling molecules, 
and surface/secreted factors that have been implicated in T cell 
function and differentiation, including Gadd45, Map3k1 
(MEKK1), TLR2, Tnfrsf9 (4-1BB), and, as expected, IL-17. 
The canonical HIF1 target gene VEGF was also diminished 
in HIF1/ cells (Fig. 2 G). These findings reveal diverse 
HIF1 target genes in T cells that may collectively control 
T cell metabolism and differentiation.
To investigate the physiological significance of HIF1 in 
vivo, we immunized WT and HIF1/ mice with the myelin 
oligodendrocyte glycoprotein (MOG)35-55 peptide emulsi-
fied in CFA. After 9 d, we isolated draining LN (DLN) cells 
and stimulated them with the MOG peptide ex vivo. Tritiated 
thymidine incorporation assays revealed that antigen-specific 
T cells from WT and HIF1/ mice proliferated to a similar 
(Zhou et al., 2008). Thus, dysregulated IL-23R and Foxp3 
expression in HIF1/ cells likely contributes to their im-
paired TH17 differentiation.
To further understand how HIF1 regulates TH17 differ-
entiation, we compared gene expression profiles of WT and 
HIF1/ cells differentiated toward TH17 cells using Affyme-
trix oligonucleotide arrays. A total of 581 probes showed equal 
or greater than twofold change (with false discovery rate <0.05) 
between WT and HIF1/ cells, including 194 up-regulated 
and 387 down-regulated entries upon HIF1 deficiency 
(Fig. 2 F and Table S1). We analyzed the gene list for enrich-
ment of gene ontology and canonical pathways using the 
DAVID bioinformatics databases (Huang da et al., 2009).   
Remarkably, the 10 pathways with the most significant enrich-
ment were all associated with glycolytic or related metabolic 
pathways (Fig. S3). Fig. 2 G showed the expression of a selec-
tive group of metabolic molecules, including the glycolytic 
Figure 2.  HIF1 deficiency results in 
diminished TH17 differentiation. (A) Naive  
T cells from WT and HIF1/ mice were dif-
ferentiated under TH17 conditions, followed 
by intracellular staining of IL-17. Data repre-
sent six independent experiments. (B) Effector 
TH17 cells, as described in A, were restimulated 
with 5 µg/ml of plate-bound anti-CD3) over-
night, and supernatants were collected and 
subjected to Bioplex measurement of IL-17 
and IL-2. (C) Effector TH17 cells, as described 
in A, were stimulated with anti-CD3/CD28 for 
5 h for RNA and expression analyses. Data 
represent three independent experiments.  
(D and E) Naive T cells from WT and HIF1/ 
mice were differentiated under TH17 condi-
tions for 2.5 d, and IL-23R (D) and Foxp3 (E) 
expression was examined by real-time PCR 
analyses. Data represent three independent 
experiments. (F and G) Naive T cells from WT 
and HIF1/ mice were differentiated under 
TH17 conditions for 2.5 d, and RNA was ana-
lyzed by microarrays to compare expression 
profiles between WT and HIF1/ cells (F) 
with selected genes in metabolism, tran-
scription factors/signaling pathways, and 
surface/secreted molecules presented (G). 
Heat maps display gene expression relative to 
the WT mean on a log2 scale. (H) WT and 
HIF1/ mice were immunized with MOG/
CFA and, 9 d later, DLN cells were stimulated 
with MOG for 5 d, followed by intracellular 
staining of IL-17. Data represent two inde-
pendent experiments. (I–K) WT and HIF1/ 
mice were immunized with MOG/CFA and, 9 d 
later, DLN cells were expanded with MOG and 
IL-23 for 5 d, followed by adoptive transfer 
into C57BL/6 mice to induce TH17-polarized 
transfer EAE. Disease scores were recorded 
daily (I) and, 11–12 d after transfer, mice were 
euthanized for histological analysis of spinal cord inflammation (J) with pathology scores calculated (K). **, P < 0.01. Bars, 100 µm. Data represent two 
independent experiments. Data represent the mean ± SEM.JEM Vol. 208, No. 7  1371
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TGF-  concentrations  (Fig.  3  A). 
Consistent with these findings, mRNA 
expression of Foxp3, as well as Treg 
cell–associated surface molecules such   
as Ctla4 and Gpr83, was up-regulated in HIF1/ cells   
(Fig. 3 B). Furthermore, both in an in vitro Treg cell differen-
tiation system mediated by splenic DCs (without exogenous 
cytokines) and in an ex vivo recall response after MOG 
immunization, HIF1/ T cells exhibited higher Foxp3 
induction (Fig. 3, C and D). Finally, HIF1/ cells showed 
a reduction of IL-17 expression and a reciprocal increase in 
Foxp3 levels under TH17-polarizing conditions with titrated 
amounts of IL-6 (Fig. 3 E). This is in agreement with the 
notion that the dichotomy of TH17 and Treg cell is dependent 
on an inflammatory environment, especially the concentration 
of IL-6 (Bettelli et al., 2006). Thus, HIF1 is required to 
promote TH17 but to inhibit Treg cell differentiation.
Blocking glycolysis reciprocally alters TH17  
and Treg cell differentiation
Having established an essential role for HIF1 in controlling 
the balance between TH17 and Treg cell differentiation, we next 
asked whether HIF1–dependent metabolic reprogramming 
is instrumental to such cell fate decision. Consistent with the 
selectively high glycolytic activity and HIF1 expression in 
TH17 relative to Treg cells (Fig. 1, A and B), real-time PCR 
degree (unpublished data). However, IL-17 expression was 
reduced in T cells isolated from HIF1/ mice (Fig. 2 H). 
Moreover, we expanded the DLN cells with MOG and IL-23 
and transferred the resulting cells into C57BL/6 mice. In this 
TH17-polarized transfer model of EAE (Kang et al., 2010), dis-
ease development was significantly delayed in mice receiving 
the HIF1/ cells comparing those receiving the WT cells 
(Fig. 2 I). Histological analyses showed less prominent leuko-
cyte infiltration and inflammation in the spinal cords of mice 
transferred with HIF1/ cells (Fig. 2, J and K). Therefore, 
HIF1 is required for TH17 differentiation in vivo and con-
tributes to TH17-dependent CNS inflammation.
The balance of TH17 and Treg cell differentiation depends  
on HIF1
An abnormal up-regulation of Foxp3 mRNA expression in 
HIF1/ cells during TH17 differentiation (Fig. 2 E) prompted 
us to test whether HIF1 controls the balance between the 
closely regulated TH17 and Foxp3+ Treg cell lineages. Deficiency 
of HIF1 considerably increased the Foxp3+ population when 
naive T cells were activated in the presence of TGF-, with 
more prominent changes observed under low nonsaturating 
Figure 3.  HIF1 deficiency promotes 
Treg cell differentiation and alters TH17/
Treg cell balance. (A) Naive T cells from WT 
and HIF1/ mice were activated in the 
presence of 1 or 10 ng/ml TGF- for 5 d, 
followed by Foxp3 staining. Data represent 
four independent experiments. (B) Naive  
T cells from WT and HIF1/ mice were 
activated in the presence of IL-2 and vary-
ing amount of TGF- for 5 d, followed by 
real-time PCR analyses of Foxp3, Ctla4, and 
Gpr83 expression. (C) Naive T cells from WT 
and HIF1/ mice were stimulated with 
splenic DCs and anti-CD3 for 5 d, and Foxp3 
mRNA was analyzed. (D) WT and HIF1/ 
mice were immunized with MOG and, 9 d 
later, DLN cells were stimulated with MOG 
for 5 d, followed by Foxp3 staining. (E) Naive 
T cells from WT and HIF1/ mice were 
differentiated under TH17 conditions with 
varying doses of IL-6 for 5 d, followed by 
intracellular staining of IL-17 and Foxp3. 
Data represent four independent experi-
ments. (F) WT naive T cells were differenti-
ated under TH17 or Treg cell–inducing 
conditions, followed by real-time PCR  
analyses of glycolytic molecules. Expression 
levels in naive T cells were set to 1. Data 
represent two independent experiments. 
Data represent the mean ± SEM (B and C)  
or the mean ± SD (F).1372 A metabolic checkpoint in T cell differentiation | Shi et al.
comparison, we treated T cells with the mTOR inhibitor ra-
pamycin, which blocks mTOR-dependent metabolic pathways 
including glycolysis (Düvel et al., 2010; Powell and Delgoffe, 
2010). Similar to the effects of 2-DG, treatment of T cells 
with rapamycin inhibited the glycolytic activity and the pro-
duction of IL-17 (Fig. 4, A and B). Moreover, mRNA ex-
pression levels of TH17-associated cytokines, including IL-17, 
IL-17F, IL-21, and IL-22, were all inhibited by 2-DG and 
rapamycin treatments (Fig. 4 C). Notably, because the cells 
were treated with the pharmacological inhibitors during their 
differentiation but not at the time of acute restimulation of 
effector TH17 cells, the diminished production of these TH17 
signature cytokines reflected a specific effect of glycolytic in-
hibition on the differentiation.
To test the effects of 2-DG on the development of TH17 
cells in vivo, we transferred naive T cells (CD62LhiCD44lo) 
from OT-II TCR-transgenic mice (specific for OVA323-339; 
analyses revealed that the expression of metabolic genes involved 
in glycolysis was much higher in differentiating TH17 cells 
than in Treg cells (Fig. 3 F).
To directly test the importance of the metabolic repro-
gramming in T cell differentiation, we cultured naive T cells 
under TH17-polarizing conditions in the presence or absence 
of 2-DG, a prototypical inhibitor of the glycolytic pathway 
via blocking hexokinase, the first rate-limiting enzyme of gly-
colysis. As expected, 2-DG treatment of T cells reduced the 
glycolytic activity (Fig. 4 A). Importantly, treatment of T cells 
with 2-DG resulted in diminished production of IL-17 
(Fig. 4 B). Although high concentrations of 2-DG (10–50 mM) 
have been shown to inhibit T cell proliferation (Cham et al., 
2008), at the lower dose of 2-DG used in this study (1 mM), 
we observed minimal inhibitory effects of 2-DG on cell pro-
liferation, as indicated by the indistinguishable CSFE dilution 
between control and 2-DG–treated samples (Fig. 4 B). As a 
Figure 4.  Blocking glycolysis reciprocally 
reduces TH17 but promotes Treg cell differ-
entiation. (A) Naive T cells were differenti-
ated under TH17 conditions for 2.5 d in the 
presence of vehicle (Ctrl), 1 mM 2-DG, or 50 nM 
rapamycin (Rapa). Glycolytic activity was 
measured as described in Fig. 1 A. Data repre-
sent two independent experiments. (B) Naive  
T cells were labeled with CFSE and differenti-
ated under TH17 conditions in the presence of 
vehicle, 1 mM 2-DG, or 50 nM rapamycin, 
followed by intracellular staining of IL-17. 
Data represent six independent experiments. 
(C) Differentiated TH17 cells, as described in  
B, were stimulated with anti-CD3 for 5 h and 
used for real-time PCR analyses of cytokine 
gene expression. Data represent three inde-
pendent experiments. (D) Naive OT-II T cells 
(Thy1.1+) cells were transferred into C57BL/6 
mice and immunized with OVA, with daily 
treatment of 2-DG or vehicle controls. DLN 
cells were analyzed 6 d later for the propor-
tion of the IL-17+ population among donor  
T cells. Data represent two independent ex-
periments. (E) Naive T cells were treated with 
vehicle, 2-DG, or rapamycin and activated in 
the presence of 1 ng/ml TGF- for 5 d, fol-
lowed by Foxp3 staining. Data represent four 
independent experiments. (F) Naive T cells 
were treated with vehicle, 2-DG, or rapamycin 
and differentiated under TH17 conditions, except 
for the lower dose of IL-6 used (0.2 ng/ml), 
followed by intracellular staining of IL-17 and 
Foxp3. Data represent four independent ex-
periments. (G–I) WT mice were immunized 
with MOG and, 9 d later, DLN cells were ex-
panded with MOG and IL-23 in the presence 
or absence of 2-DG for 5 d. An aliquot of cells 
were analyzed by intracellular staining for 
Foxp3 and IL-17 expression (G), with the remaining cells transferred into C57BL/6 mice for the induction of TH17-polarized transfer EAE (H). Spinal cord 
was analyzed for pathology scores at day 12 after transfer (I). *, P < 0.05; **, P < 0.01. Data represent two independent experiments. Data represent the 
mean ± SD (A) or the mean ± SEM (C, D, H, and I).JEM Vol. 208, No. 7  1373
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model  of  EAE,  with  2-DG  added 
during the in vitro expansion of DLN 
cells. Such treatment resulted in re-
duced IL-17+ cells and simultaneous 
increase of Foxp3+ Treg cells (Fig. 4 G). 
When  these  cells  were  transferred 
into  C57BL/6  recipients,  2-DG–
treated cells exhibited markedly re-
duced ability to cause EAE (Fig. 4 H). 
This was associated with diminished 
leukocyte infiltration and spinal cord 
inflammation, as revealed by histo-
logical analyses (Fig. 4, H and I; and 
Fig. S4 C). Therefore, blocking glycolysis alters TH17 and 
Treg cell differentiation and protects mice from EAE.
mTOR is required for HIF1 induction  
in TH17 cell differentiation
A key role for HIF1 to direct reciprocal TH17 and Treg cell 
differentiation prompted us to identify upstream molecular 
pathways responsible for HIF1 induction in differentiating 
TH17 cells (Fig. 1 B). Because cell fate decision between 
TH17 and Treg cells is critically dependent on IL-6, we analyzed 
HIF1 expression in T cells stimulated with varying amount 
of IL-6. HIF1 was induced by IL-6 in a dose-dependent 
manner (Fig. 5 A), indicating an important role for IL-6 sig-
naling in HIF1 induction.
Recent experiments have shown that HIF1 is responsi-
ble for the glycolytic response downstream of mTOR (Düvel 
et al., 2010). As rapamycin treatment was similar to HIF1 
deficiency at altering TH17 and Treg cell differentiation, we 
hypothesized that rapamycin-sensitive mTOR signaling is 
important for HIF1 induction in T cells. To test this, we 
treated T cells with rapamycin and examined HIF1 expression. 
Blocking mTOR activity with rapamycin in differentiating 
Thy1.1+) into C57BL/6 mice and immunized them with anti-
gen, followed by daily 2-DG treatment in vivo. At day 6 after 
immunization, we isolated DLN cells and measured IL-17 
production in donor-derived cells by intracellular cytokine 
staining. Treatment of 2-DG resulted in significantly reduced 
IL-17–expressing cells (Fig. 4 D). Moreover, mRNA expres-
sion and secretion of IL-17 were considerably reduced after 
2-DG treatment (Fig. S4, A and B). We therefore conclude 
that TH17 differentiation depends on the glycolytic activity.
We next examined the effects of 2-DG and rapamycin on 
Treg cell generation. Rapamycin has been shown to potenti-
ate Treg cell differentiation (Haxhinasto et al., 2008; Sauer   
et al., 2008; Cobbold et al., 2009). Similar to the effect of ra-
pamycin, 2-DG also promoted Treg cell generation (Fig. 4 E). 
Furthermore,  under  conditions  that  allowed  simultaneous 
generation of TH17 and Treg cells, 2-DG and rapamycin di-
minished IL-17 production but promoted Foxp3 induction 
(Fig. 4 F). Collectively, these results indicate that inhibition 
of glycolysis blocks TH17 development while promoting   
Treg cell generation.
To evaluate the contribution of glycolysis to autoimmune 
inflammation in vivo, we used the TH17-polarized transfer 
Figure 5.  mTOR activity is required for 
HIF1 induction in TH17-differentiating 
cells. (A) WT naive T cells were activated by 
anti-CD3/CD28 in the presence of various 
concentrations of TGF- and IL-6 for 2.5 d, 
and HIF1 expression was analyzed by real-
time PCR (levels in activated cells without 
TGF-/IL-6 were set to 1). (B) Naive T cells 
were treated with vehicle (Ctrl) or 50 nM 
rapamycin (Rapa) and differentiated under 
TH17 conditions. HIF1 expression was ex-
amined by real-time PCR analyses (levels in 
naive cells were set to 1). (C) Naive T cells 
were differentiated as described in  
B, and expression of glycolytic molecules 
was examined by real-time PCR analyses. 
Data in Fig. 5 are representative of at least 
two independent experiments. Data repre-
sent the mean ± SEM (A) or the mean ± SD 
(B and C). (D) HIF1–induced metabolic 
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sion program. Given the evolutionarily conserved nature of 
the hypoxic response and glycolytic pathway, we propose 
that the adaptive immune system has evolved to adopt these 
basic metabolic machineries to regulate cell fate decision of 
helper T cells. Furthermore, the selective dependence of TH17 
differentiation on HIF1–mediated metabolic reprogramming 
has provided novel targets for therapeutic intervention of auto-
immune and inflammatory diseases elicited by TH17 cells.
MATERIALS AND METHODS
Mice. HIF1flox/flox and OT-II TCR-transgenic mice on the C57BL/6 
background were purchased from The Jackson Laboratory (Ryan et al., 
2000). Mice at 7–12 wk of age were used. All mice were kept in specific 
pathogen-free conditions within the Animal Resource Center at St. Jude 
Children’s Research Hospital. Animal protocols were approved by the 
Institutional Animal  Care  and  Use  Committee  of  St.  Jude  Children’s   
Research Hospital.
Flow cytometry. For analysis of surface markers, cells were stained in PBS 
containing 2% (wt/vol) BSA and the appropriate antibodies from eBiosci-
ence. Foxp3 staining was performed according to the manufacturer’s instruc-
tions  (eBioscience).  For  intracellular  cytokine  staining,  T  cells  were 
stimulated for 4–5 h with phorbol 12-myristate 13-acetate (PMA) and iono-
mycin in the presence of monensin before being stained according to the 
manufacturer’s instructions (BD). Simultaneous Foxp3 and IL-17 staining 
was performed using Foxp3 staining procedure after 4 h of stimulation with 
PMA and ionomycin. Flow cytometry data were acquired on an upgraded 
five-color FACScan or multi-color LSRII (BD) and were analyzed with 
FlowJo software (Tree Star).
Cell purification and culture. Lymphocytes were isolated from spleen 
and peripheral LNs and naive T cells were sorted on a MoFlow (Beckman 
Coulter) or Reflection (i-Cyt), as described previously (Liu et al., 2010). 
Sorted naive T cells (CD4+CD62LhiCD44loCD25) were used for in vitro 
culture in Click’s medium (plus -mercaptoethanol) supplemented with 10% 
(vol/vol) FBS and antibiotics. T cells were activated with 2 µg/ml anti-CD3 
(2C11; Bio X Cell), 2 µg/ml anti-CD28 (37.51; Bio X Cell), and 100 U/ml 
human IL-2. For Treg cell differentiation, cultures were supplemented with 
1 or 10 ng/ml human TGF-1. For TH1 conditions, 3.5 ng/ml IL-12 
and 10 µg/ml anti–IL-4 (11B11; Bio X Cell) were added. For TH2 condi-
tions, 10 ng/ml IL-4 and 10 µg/ml anti–IFN- were added. For TH17   
conditions, 10 µg/ml anti–IL-2, 10 µg/ml anti–IL-4, 10 µg/ml anti–IFN-,   
2 ng/ml TGF-1, 20 ng/ml IL-23, and 20, 2, or 0.2 ng/ml IL-6 were in-
cluded in cultures, and for certain experiments, only TGF-1 and IL-6 were 
used, as indicated. For DC–T cell co-culture, 5 × 104 CD11c+ DCs purified 
from spleens and 2.5 × 105 naive T cells were cultured in the presence of 
anti-CD3  without  exogenous  cytokines.  For  pharmacological  inhibitor 
treatments, cells were incubated with vehicle, 0.5–1 mM 2-DG (Sigma-
Aldrich), or 10–50 nM rapamycin (EMD) at the onset of cultures.
RNA and immunoblot analysis. RNA was extracted with an RNeasy kit   
(QIAGEN), and cDNA was synthesized with Superscript III/II reverse tran-
scription (Invitrogen). Real-time PCR was performed as described previously   
(Liu et al., 2009), and the expression of each target gene is presented as the 
fold change relative to the expression of WT control samples. Primer sequences 
used  to  determine  expression  of  glycolytic  molecules  were:  HIF1  
(forward, 5-AGCTTCTGTTATGAGGCTCACC-3; reverse, 5-TGAC-
TTGATGTTCATCGTCCTC-3), Glut1/Slc2a1 (forward, 5-CAGTTC-
GGCTATAACACTGGTG-3;  reverse,  5-GCCCCCGACAGAGAA-
GATG-3), HK2 (forward, 5-TGATCGCCTGCTTATTCACGG-3; 
reverse,  5-AACCGCCTAGAAATCTCCAGA-3),  LDH-  (forward, 
5-CATTGTCAAGTACAGTCCACACT-3; reverse, 5-TTCCAATTA-
CTCGGTTTTTGGGA-3), PKM (forward, 5-GCCGCCTGGACATT-
GACTC-3; reverse, 5-CCATGAGAGAAATTCAGCCGAG-3), MCT4 
TH17  cells  markedly  inhibited  the  induction  of  HIF1 
(Fig. 5 B). Consistent with these findings, the induction of 
transporters Glut1 and MCT4, as well as various glycolytic 
enzymes, was substantially diminished by rapamycin treat-
ment (Fig. 5 C). In contrast, 2-DG treatment, at the dose that 
was sufficient to alter TH17 and Treg cell differentiation, had 
a minimal effect on the RNA levels of HIF1 and the meta-
bolic molecules (Fig. S5, A and B). This result confirmed a 
role for 2-DG to directly inhibit glycolytic enzyme activity 
and excluded a potential indirect effect of 2-DG on regulating 
mTOR activity. Consistent with a high glycolytic activity 
in TH1 and TH2 lineages (Fig. 1 A), 2-DG treatment was also 
capable of diminishing their differentiation (Fig. S5 C). Al-
though mTOR is required for the generation of TH1 and 
TH2 cells (Delgoffe et al., 2009), HIF1 was not strongly in-
duced under TH1- and TH2-polarizing conditions (Fig. 1 B) 
or involved in their functional differentiation (Fig. S2 C). 
Collectively, HIF1 is selectively expressed in TH17 cells and 
its induction depends on IL-6 signaling and mTOR activity, 
whereas the glycolytic pathway contributes to TH1 and TH2 
differentiation in a HIF1–independent manner.
Collectively,  our  studies  demonstrate  that  an  elevated 
glycolytic activity is not only associated with TH17 cell dif-
ferentiation but that the glycolytic machinery is actively reg-
ulated to direct the differentiation of TH17 and Treg cells. This 
process  is  programmed  by  the  transcription  factor  HIF1 
through stimulating a glycolytic gene expression program. 
Therefore, the HIF1–dependent glycolytic pathway serves 
as a metabolic checkpoint to distinguish cell fate decision be-
tween these two closely related T cell lineages. We provide 
further evidence that mTOR signaling is essential to induce 
HIF1 expression in TH17 cells, suggesting that the HIF1–
dependent glycolytic pathway is an integral component down-
stream of mTOR to mediate TH17 and Treg cell differentiation 
(Fig. 5 D; Delgoffe et al., 2009; Powell and Delgoffe, 2010). 
In contrast, deficiency of HIF1 did not substantially alter 
TH1 and TH2 differentiation, indicating a HIF1–independent 
glycolytic pathway for the generation of these effector lin-
eages. Interestingly, depletion of amino acids with the small 
molecule halofuginone has recently been shown to selec-
tively inhibit TH17 cell differentiation (Sundrud et al., 2009). 
Therefore, TH17 cell differentiation has selective bioenergetic 
requirements for glucose and amino acid metabolism. Con-
versely, generation of antigen-specific Treg cells is enhanced 
by amino acid depletion (Cobbold et al., 2009) or inhibition 
of glucose metabolism (this study). Recently added evidence 
further suggests that Treg cells preferentially use fatty acids and 
inhibition of fatty acid -oxidation impairs Treg cell differen-
tiation (Michalek et al., 2011). Notably, although overexpres-
sion of HIF1 has been shown to enhance Foxp3 expression 
(Ben-Shoshan et al., 2008), our results with HIF1–deficient 
and 2-DG–treated T cells have clearly established a negative 
role for HIF1–induced metabolic reprogramming in Treg cell 
development. To our knowledge, these studies identify the 
first evidence that the glycolytic pathway and helper T cell dif-
ferentiation are linked by the HIF1–mediated gene expres-JEM Vol. 208, No. 7  1375
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microarray data was deposited into the GEO series database under accession 
number GSE29765.
Bioplex assay. Differentiated effector cells were restimulated with anti-
CD3 overnight and supernatants were harvested. Cytokine levels in the 
supernatants were measured using MILLIPLEX kits for mouse cytokine/
chemokine according to the manufacturer’s instruction (Millipore).
Glycolysis flux assay. Glycolysis of naive or effector cells was determined 
by measuring the detritiation of [3-3H]-glucose (Hue et al., 1984). In brief, 
the assay was initiated by adding 1 µCi [3-3H]-glucose (PerkinElmer) and,   
2 h later, medium was transferred to microcentrifuge tubes containing 50 µl 
5 N HCL. The microcentrifuge tubes were then placed in 20-ml scintilla-
tion vials containing 0.5 ml water and the vials capped and sealed. 3H2O was 
separated from un-metabolized [3-3H]-glucose by evaporation diffusion for 24 h 
at room temperature. Cell-free sample containing 1 µCi 3H-glucose was in-
cluded as a background control.
Statistical analysis. P-values were calculated with Student’s t test. P-values 
<0.05 were considered significant.
Online supplemental material. Fig. S1 shows the normal development, 
proliferation, and apoptosis of T cells in HIF1/ mice. Fig. S2 shows the 
effects of HIF1 deficiency on effector T cell differentiation. Fig. S3 shows 
the enrichment of metabolic pathways in HIF1 gene targets. Fig. S4 shows 
the in vivo effects of 2-DG on IL-17 expression and EAE pathogenesis. Fig. S5 
shows the effects of 2-DG on metabolic gene expression and TH1/TH2 dif-
ferentiation. Table S1 lists the 581 probes that were differentially expressed 
between WT and HIF1/ TH17 cells. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20110278/DC1.
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